Exagen Inc (XGN): Growth-Adjusted Market Cap to Net Income

Stable demand for AVISE tests ensures a steady cash flow for Exagen Inc. (XGN), which confirms the price-to-earnings ratio relative to the EPS growth forecast. The value of 0.00 characterizes this level. Business efficiency is based on the robotization of biomarker analysis using AI. Automation eliminates routine during data interpretation, although blood collection remains the responsibility of personnel.

Exagen Diagnostics (XGN): Price/Earnings to Growth Ratio from 07/04/2022 to 11/13/2026

Exagen Inc. (XGN) - metric breakdowns and financial figures

- current quotes and average value forecast:

Market Price exagen.com|XGN - Price Target Chart

- stock exchange capitalization data:

Market Capitalization Exagen Diagnostics|XGN - Enterprise Value

- company book value details:

Net Assets per Share Exagen Inc.|XGN - Company Book Value|Market Capitalization to Book Value exagen.com|XGN - Company Total Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

XGN - Company Net Income|Net Profit Forecast Exagen Inc.|XGN - Price to Earnings Ratio|Future Price to Earnings Multiple exagen.com|XGN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Exagen Diagnostics|XGN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Exagen Inc.|XGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months exagen.com|XGN - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Exagen Inc.

General company analysis:XGN Exagen Inc

To identify fundamental sector leaders, analysts utilize a comparison of market capitalization to earnings growth rates, where a value below one signals that an asset is undervalued. This PEG ratio measures the business's margin of safety, reflecting Exagen Inc. (XGN) 's ability to monetize expanded insurance coverage and rheumatologist loyalty to the AVISE system through accelerated profit growth.

Competing companies

A - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Quest DGX|Growth-Adjusted Market Cap to Net Income Illumina Platform (ILMN)|Exact Sciences - PEG Multiple|Growth-Adjusted Market Cap to Net Income revvity.com RVTY|Bio-Rad (BIO) - Price/Earnings to Growth Ratio|NNNN - Growth-Adjusted Market Cap to Net Income|SHC (Sterigenics) - PEG Multiple|Price to Earnings Adjusted for Growth Rate QuidelOrtho Inc. QDEL|Price/Earnings to Growth Multiple OPK (OPKO Health, Inc.)|CareDx, Inc. - Growth-Adjusted P/E Ratio|PEG Multiple MRVI (Maravai LifeSciences Holdings, Inc.)|PEG Multiple Fulgent Genetics Inc FLGT|Fluidigm - PEG Multiple|Price to Net Income Growth Ratio Cytek Corp (CTKB)|OSUR: PEG Multiple|Price to Earnings Adjusted for Growth Rate mdxhealth.com (MDXH)|Price/Earnings to Growth Ratio Lucid Diagnostics|Growth-Adjusted P/E Ratio PRE (Prenetics Global Ltd)|Price/Earnings to Growth Multiple IMDX (Insight Molecular Diagnostics)|TRIB (trinitybiotech.com) - Growth-Adjusted Payback Ratio|PEG Multiple PRPH (ProPhase Labs, Inc.)|Growth-Adjusted Market Cap to Net Income ainos.com (AIMD)|CODX - Price/Earnings to Growth Ratio|HSCS (Heart Test Laboratories, Inc.) - Growth-Adjusted P/E Ratio|BMRA: PEG Multiple|Price/Earnings to Growth Multiple Cardio Diagnostics Holdings|Price/Earnings to Growth Multiple ONCO|viraxbiolabs.com (VRAX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple BJDX (Bluejay Diagnostics, Inc.)|Aspira Women's Health, Inc. - Growth-Adjusted P/E Ratio|PEG Multiple AXDX (Accelerate Diagnostics, Inc)|Price to Net Income Growth Ratio Centogene NV|ENZ - Price/Earnings to Growth Ratio|FRES (Fresh2 Group Limited) - Growth-Adjusted P/E Ratio|gtglabs.com (GENE) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple 23andMe Holding Co|PMD (Psychemedics Corp) - PEG Multiple